• 作者：Marí ; a Ferná ; ndez-Ibieta^a ; ^{mfndezibieta2@hotmail.com} ; Jose Tomá ; s Ramos^a ; Maria Isabel Gonzá ; lez-Tomé ; ^b ; Sara Guillé ; n^a ; Marisa Navarro^c ; Maria José ; Cilleruelo^d
• 关键词：Virus de la inmunodeficiencia humana ; Vacuna ; Virus de la hepatitis A ; Virus de la hepatitis B
• 刊名：Enfermedades Infecciosas y Microbiolog铆a Cl铆nica
• 出版年：2009
• 期刊代码：pca153_0213005X
• 类别：med
• 出版时间：October 2009
• 卷：27
• 期：8
• 页码：449-452
• 文件大小：166 K

Introduction

Patients coinfected with HIV and hepatitis B virus (HBV) have a higher risk of developing chronic HBV infection and a higher risk of hepatotoxicity. Hepatitis A virus (HAV) in HIV-infected patients may require antiretroviral treatment interruption, producing prolonged viremia. In this study, we assess the prevalence of protective antibodies in these patients.

Methods

A cross-sectional study was conducted to determine the prevalence of IgG antibodies against HAV and antibody against HBs (anti-HBs) in a cohort of 121 HIV-infected children and adolescents (1鈥?9 years), followed-up in 4 public hospitals in Madrid (Spain).

Results

Among the total, 12.4%(95%CI: 7.1鈥?9.6%) of children and adolescents had positive serology for HAV. Children of immigrant origin presented a higher percentage than children born in Spain: 50%vs. 6.2%, respectively (P<0.001). In addition, 16.5%(95%CI: 10.4鈥?4.3) of the study population had protective anti-HBs. A higher percentage of children with anti-HBs antibodies was seen in CDC clinical category A: 20%vs. 16%of those in clinical category B vs. 9.4%of those in clinical category C (P=0.19). The percentage of positive-positive children progressively decreased according to the years elapsed since HBV vaccination.

Discussion

Most HIV-infected children and adolescents have no protective antibodies against natural infection by HBV and HAV. More studies are needed to define the best vaccination strategy to achieve a higher percentage of patients protected against these infections.